Estradiol and Zoster Associated Orofacial Pain
雌二醇和带状疱疹相关的口面部疼痛
基本信息
- 批准号:10021211
- 负责人:
- 金额:$ 9.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-24 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAreaAromataseAromatase InhibitorsAttenuatedBehavioral AssayBindingBiological AssayBiologyBrain regionCell CountCellsChronic DiseaseClustered Regularly Interspaced Short Palindromic RepeatsComplicationDNADiagnosisDiestrusDiseaseElectrophoretic Mobility Shift AssayEstradiolEstrogen Receptor alphaEstrogensFOS geneFemaleGene ExpressionGenesGlutamate DecarboxylaseGoalsGonadal Steroid HormonesHerpes zoster diseaseHerpesvirus Type 3HumanHypersensitivityImmuneInterneuronsLateralLuciferasesMeasurementMeasuresMolecularMutateNational Institute of Dental and Craniofacial ResearchNeural InhibitionNeuronsNociceptionOrofacial PainPainPathogenesisPathologyPathway interactionsPatientsPharmaceutical PreparationsPostherpetic neuralgiaProductionProestrusPromoter RegionsRattusReporterReportingReticular CellRoleSex DifferencesSignal TransductionSiteSkinSomatosensory CortexStainsStructure of trigeminal ganglionSymptomsTechnologyTestingThalamic structureTimeTrigeminal NucleiVaccinationWomanattenuationawakebasechromatin immunoprecipitationchronic paincingulate cortexexperimental studygamma-Aminobutyric Acidinhibitory neuroninsightknock-downmalemenmidbrain central gray substancemutantnociceptive responsenovelorofacialpain modelpain reductionpromoterpublic health relevancereactivation from latencysex disparitytranscription factorvesicular GABA transporterzona incerta
项目摘要
ABSTRACT
People with herpes zoster (HZ) or “shingles” can suffer from orofacial pain. Orofacial HZ is caused by the
reactivation of latent varicella zoster virus (VZV) in the trigeminal ganglia. Importantly, women report HZ pain
three times more often than men, but the mechanism for this sex disparity is unknown. A screen by our lab of
over 20,000 genes in five different regions of the orofacial pain pathway revealed that the greatest change in
gene expression occurred in the thalamus, such that glutamate decarboxylase 2 (GAD2) and vesicular GABA
transporter (VGAT) were elevated at proestrus (high 17 β-estradiol, E2) but not diestrus (low E2). In
preliminary studies we showed that female rats have a greater VZV induced orofacial nociceptive response in
comparison to males; mirroring the human sex difference. We also showed that reducing E2 production in
male and female rats increases their nociceptive response and lastly, knock-down of VGAT expression in the
thalamus increased the nociceptive response. Based on these studies we hypothesized that E2 attenuates
orofacial nociception by increasing GAD2 or VGAT, enhancing GABAergic neural inhibition within the
thalamus to reduce pain. To test this hypothesis, Aim 1 will characterize thalamic control of the VZV induced
orofacial nociceptive response. The working hypothesis for Aim 1 is that GABA interneurons inhibit neurons
in the thalamus to reduce VZV induced nociception. To test this hypothesis first, VZV induced nociception
and neuronal activity will be recorded after attenuating inhibitory interneurons. Second, nociception and
neuronal activity will be determined after modulating GAD2 and VGAT expression in these interneurons. Aim
2 will determine the role of sex steroids in modulating the VZV induced nociceptive response. Our working
hypothesis is that E2 will increase expression of VGAT and GAD2 in the thalamus causing attenuation of
neuronal activity and the nociceptive response. To test this hypothesis first, the nociceptive response and
neuronal activity will be measured in female and male rats after administering E2 or reducing E2 production.
Second, nociception and neuronal activity will be measured after knock-down of GAD2 and VGAT expression
in rats with varied E2 levels. Aim 3 will characterize the mechanism by which sex steroids modulate VGAT
and GAD2 to affect the VZV induced orofacial nociceptive response. Our working hypothesis is that E2 binds
to estrogen receptor alpha (ERα) causing increased expression of VGAT and GAD2 in the thalamus resulting
in attenuation of nociception. To test this idea, the nociceptive response and neuronal activity will be
quantitated in rats after mutating ERα promoter sites using CRISPR/Cas9 technology. From these three aims
we expect to determine 1) that GABA interneurons inhibit thalamic signaling to reduce orofacial pain, 2) that
GAD2 and VGAT increases in these neurons through an ERα dependent mechanism, and 3) that GAD2 and
VGAT are responsible, in part, for the sex difference observed in HZ pain. Identifying a mechanism by which
E2 affects HZ-associated pain will provide new targets for treating people suffering from this chronic disorder.
抽象的
带状疱疹 (HZ) 或“带状疱疹”患者可能会出现口面部疼痛。
三叉神经节中潜伏的水痘带状疱疹病毒 (VZV) 重新激活 重要的是,女性会出现带状疱疹疼痛。
是男性的三倍,但这种性别差异的机制尚不清楚。
口面部疼痛通路五个不同区域的 20,000 多个基因显示,最大的变化是
基因表达发生在丘脑,例如谷氨酸脱羧酶 2 (GAD2) 和囊泡 GABA
转运蛋白 (VGAT) 在发情前期升高(高 17 β-雌二醇,E2),但在发情间期则不升高(低 E2)。
初步研究表明,雌性大鼠在 VZV 诱导下的口面部伤害性反应更强
与男性比较;反映了人类的性别差异。
雄性和雌性大鼠的伤害性反应增加,最后,VGAT 表达被敲低
根据这些研究,我们发现 E2 会减弱丘脑的伤害性反应。
通过增加 GAD2 或 VGAT 来增强口面部伤害感受,增强 GABA 能神经抑制
为了检验这一假设,目标 1 将表征丘脑对 VZV 诱导的控制。
目标 1 的工作假设是 GABA 中间神经元抑制神经元。
丘脑中减少 VZV 诱发的伤害感受 首先检验这一假设,VZV 诱发伤害感受。
减弱抑制性中间神经元后,将记录神经活动。
调节这些中间神经元中的 GAD2 和 VGAT 表达后,将确定神经元活性。
2 将确定性类固醇在调节 VZV 诱导的伤害性反应中的作用。
假设 E2 会增加丘脑中 VGAT 和 GAD2 的表达,从而导致
神经活动和伤害性反应首先要检验这个假设,伤害性反应和
在施用 E2 或减少 E2 产生后,将测量雌性和雄性大鼠的神经元活动。
其次,敲除 GAD2 和 VGAT 表达后测量伤害感受和神经活动
目标 3 将描述性类固醇调节 VGAT 的机制。
和 GAD2 影响 VZV 诱导的口面部伤害性反应 我们的工作假设是 E2 结合。
雌激素受体 α (ERα) 导致丘脑中 VGAT 和 GAD2 表达增加
为了测试这个想法,将伤害感受反应和神经活动。
使用 CRISPR/Cas9 技术对大鼠中的 ERα 启动子位点进行突变后进行定量。
我们期望确定 1) GABA 中间神经元抑制丘脑信号传导以减轻口面部疼痛,2)
GAD2 和 VGAT 通过 ERα 依赖性机制在这些神经元中增加,并且 3) GAD2 和
VGAT 在一定程度上导致了带状疱疹疼痛的性别差异。
E2 影响带状疱疹相关的疼痛将为治疗患有这种慢性疾病的人提供新的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILLIP R KRAMER其他文献
PHILLIP R KRAMER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILLIP R KRAMER', 18)}}的其他基金
Estradiol and Zoster Associated Orofacial Pain
雌二醇和带状疱疹相关的口面部疼痛
- 批准号:
10359728 - 财政年份:2018
- 资助金额:
$ 9.75万 - 项目类别:
Estradiol and Zoster Associated Orofacial Pain
雌二醇和带状疱疹相关的口面部疼痛
- 批准号:
9905497 - 财政年份:2018
- 资助金额:
$ 9.75万 - 项目类别:
Estrogenic Regulation of Inflammation Related to TMJD
雌激素对颞下颌关节病相关炎症的调节
- 批准号:
7052843 - 财政年份:2003
- 资助金额:
$ 9.75万 - 项目类别:
Estrogenic Regulation of Inflammation Related to TMJD
雌激素对颞下颌关节病相关炎症的调节
- 批准号:
6881218 - 财政年份:2003
- 资助金额:
$ 9.75万 - 项目类别:
Estrogenic LXR Alpha Response /Cholesterol Homeostasis
雌激素 LXR Alpha 反应/胆固醇稳态
- 批准号:
6614747 - 财政年份:2003
- 资助金额:
$ 9.75万 - 项目类别:
Estrogenic Regulation of Inflammation Related to TMJD
雌激素对颞下颌关节病相关炎症的调节
- 批准号:
6775614 - 财政年份:2003
- 资助金额:
$ 9.75万 - 项目类别:
Estrogenic Regulation of Inflammation Related to TMJD
雌激素对颞下颌关节病相关炎症的调节
- 批准号:
6685744 - 财政年份:2003
- 资助金额:
$ 9.75万 - 项目类别:
相似国自然基金
秦岭生态效益转化与区域绿色发展模式
- 批准号:72349001
- 批准年份:2023
- 资助金额:200 万元
- 项目类别:专项基金项目
我国西南地区节点城市在次区域跨国城市网络中的地位、功能和能级提升研究
- 批准号:72364037
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
农产品区域公用品牌地方政府干预机制与政策优化研究
- 批准号:72373068
- 批准年份:2023
- 资助金额:41 万元
- 项目类别:面上项目
通过自主研发的AAV8-TBG-LOX-1基因治疗技术祛除支架区域氧化型低密度脂蛋白抑制支架内新生动脉粥样硬化研究
- 批准号:82370348
- 批准年份:2023
- 资助金额:47 万元
- 项目类别:面上项目
政府数据开放与资本跨区域流动:影响机理与经济后果
- 批准号:72302091
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Pulmonary Pathophysiologic Mechanisms of Chloropicrin and Phosgene
氯化苦和光气的肺部病理生理机制
- 批准号:
10708551 - 财政年份:2023
- 资助金额:
$ 9.75万 - 项目类别:
Breast cancer neoadjuvant endocrine therapy during the Covid-19 pandemic: Opportunity for a new treatment paradigm?
Covid-19大流行期间的乳腺癌新辅助内分泌治疗:新治疗模式的机会?
- 批准号:
10425018 - 财政年份:2022
- 资助金额:
$ 9.75万 - 项目类别:
Web-based Pain Coping Skills Training to Improve Pain and Poor Adherence caused by Aromatase Inhibitor-Associated Arthralgia In Breast Cancer Survivors (SKIP-Arthralgia): A Randomized Controlled Trial
基于网络的疼痛应对技能培训,以改善乳腺癌幸存者芳香酶抑制剂相关关节痛引起的疼痛和依从性差(SKIP-关节痛):一项随机对照试验
- 批准号:
10439192 - 财政年份:2022
- 资助金额:
$ 9.75万 - 项目类别:
A longitudinal, nationally representative study of cognition-related effects of breast cancer and its treatment
关于乳腺癌及其治疗的认知相关影响的纵向、全国代表性研究
- 批准号:
10709517 - 财政年份:2022
- 资助金额:
$ 9.75万 - 项目类别:
Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer
共同靶向 IL-6 和 CDK4/6 通路作为三阴性乳腺癌预防性治疗的新方法
- 批准号:
10365726 - 财政年份:2022
- 资助金额:
$ 9.75万 - 项目类别: